Allogeneic haematopoietic stem-cell transplantation (HSCT) has become a life-saving treatment option for numerous benign and malignant diseases, with more than 14 500 procedures being performed annually in Europe alone . Late-onset noninfectious pulmonary complications (NIPCs) have emerged as the main hurdle to long-term survival, affecting up to 26% of HSCT recipients and conferring 2- and 5-year survival rates of 44% and 13%, respectively [2, 3].
Interstitial lung disease is a common, largely unrecognised feature of pulmonary GvHD after stem cell transplant http://ow.ly/DWP4307mO3i
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received January 16, 2016.
- Accepted August 4, 2016.
- Copyright ©ERS 2016